Daiichi Sankyo
Daiichi Sankyo Company, Limited, commonly referred to as Daiichi Sankyo, is a prominent global pharmaceutical firm headquartered in Tokyo, Japan. Founded in 1899, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative healthcare solutions. Specialising in the research, development, and manufacturing of pharmaceuticals, Daiichi Sankyo is particularly renowned for its contributions to oncology, cardiovascular, and vaccine development. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, positioning it as a leader in the pharmaceutical industry. With a rich history marked by key milestones, Daiichi Sankyo has achieved notable success, including the development of groundbreaking therapies that have transformed treatment paradigms. Its dedication to innovation and quality has solidified its reputation as a trusted name in healthcare worldwide.
DitchCarbon Score
How does Daiichi Sankyo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Daiichi Sankyo's score of 28 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Daiichi Sankyo's reported carbon emissions
In 2023, Daiichi Sankyo reported total carbon emissions of approximately 4,602,874,000 kg CO2e globally, with 82,658,000 kg CO2e from Scope 1 and 2, and a significant 4,496,153,000 kg CO2e from Scope 3 emissions. In Japan, the company recorded total emissions of about 63,304,000 kg CO2e, comprising 63,004,000 kg CO2e from Scope 1 and 2. Daiichi Sankyo has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. However, the company continues to monitor and report its emissions across all relevant scopes, indicating a commitment to transparency in its environmental impact. The absence of formal reduction targets suggests a potential area for future development in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 217,257,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 304,293,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daiichi Sankyo is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
